SCHEMBL2314036

SCHEMBL2314036

CCCCCCCCCCCCCC(CC(=O)O)(C(=O)O)S(=O)(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
FFAR1 O14842 2/20 0.41
CPT2 P23786 1/20 0.41
HSPD1 P10809 1/20 0.41
BLM P54132 1/20 0.41
HSPE1 P61604 1/20 0.41
GPR84 Q9NQS5 7/20 0.39
PPARG P37231 7/20 0.39
PPARD Q03181 7/20 0.39
PPARA Q07869 7/20 0.39
HDAC11 Q96DB2 5/20 0.39
TSHR P16473 4/20 0.39
PTPN1 P18031 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TLR2 O60603 2/20 0.39
FABP4 P15090 2/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
MEN1 O00255 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28189670 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL749698 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL2418933 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL573838 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL208623 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
Tridecane SCHEMBL11754456 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL1840384 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL9836853 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL9645095 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM
SCHEMBL28135836 1.00 TDP1 (0.41) TDP1FFAR1CPT2HSPD1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120138789-A1 Phosphonium-Based Ionic Liquids and Uses LOS ALAMOS NATIONAL SECURITY, LLC (US) 2012-06-07 US claimed
EP-2350213-A1 LIQUID ELECTROPHOTOGRAPHIC INK WITH A CHARGE DIRECTOR SYSTEM Hewlett-Packard Development Company, L.P. (US) 2011-08-03 EP claimed
WO-2010053480-A1 LIQUID ELECTROPHOTOGRAPHIC INK WITH A CHARGE DIRECTOR SYSTEM HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2010-05-14 WO claimed
WO-2008136983-A1 METHOD FOR THE ENHANCING BIOCIDAL ACTIVITY HERCULES INCORPORATED (US) 2008-11-13 WO claimed
US-20080269337-A1 Method for the enhancing biocidal activity ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC 2008-10-30 US claimed
US-11939521-B2 Reuse of hypersaline brine with ionic liquids SAUDI ARABIAN OIL COMPANY (SA) 2024-03-26 US disclosed
WO-2024039814-A1 REUSE OF HYPERSALINE BRINE WITH IONIC LIQUIDS SAUDI ARABIAN OIL COMPANY (SA) 2024-02-22 WO disclosed
US-20240059958-A1 REUSE OF HYPERSALINE BRINE WITH IONIC LIQUIDS SAUDI ARABIAN OIL COMPANY (SA) 2024-02-22 US disclosed
CN-108366891-A The positive dough sheet of absorbent commodity 花王株式会社 2018-08-03 CN disclosed
CN-108368673-A Non-woven fabrics 花王株式会社 2018-08-03 CN disclosed
CN-107429199-A Compositions comprising peptidases and biosurfactants 赢创德固赛有限公司 2017-12-01 CN disclosed
CN-106232888-B Non-woven fabrics 花王株式会社 2017-09-29 CN disclosed
CN-1649955-A Dust repellant compositions PETROFERM INC (US) 2005-08-03 CN disclosed
EP-1406582-A1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM MERCK PATENT GmbH (DE) 2004-04-14 EP disclosed
US-20030078189-A1 Medicinal compositions for oral use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-04-24 US disclosed
WO-2003007906-A1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM MERCK PATENT GMBH (DE) 2003-01-30 WO disclosed
EP-1236476-A1 MEDICINAL COMPOSITIONS FOR ORAL USE Takeda Chemical Industries, Ltd. (JP) 2002-09-04 EP disclosed
EP-0402213-B1 Process for the manufacture of polyvinyl butyral and resulting products DU PONT (US) 1994-09-21 EP disclosed
EP-0402213-A1 Process for the manufacture of polyvinyl butyral and resulting products E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-12-12 EP disclosed
US-4775532-A DI(ALKYL)ADIPATE CARRIER MOBIL OIL CORPORATION (US) 1988-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078189-A1 Medicinal compositions for oral use CCR5, CXCR3, CCL5 TDP1 3951/4885FFAR1 747/4885CPT2 2499/4885
US-20120138789-A1 Phosphonium-Based Ionic Liquids and Uses SRMS, PHOSPHO1, TRMT1L TDP1 1027/4885FFAR1 4766/4885CPT2 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.